A new study published this week in Molecular Psychiatry by Emory University researchers has revealed a promising new avenue for treating motivational deficits in patients suffering from depression.
Sep 23, 2024
0
73
Scientists may have uncovered the root cause of psoriasis, a chronic and sometimes debilitating skin disease that affects 2–3% of the global population. The condition is characterized by red, scaly patches that impact the ...
Sep 26, 2024
0
36
Researchers at the University of Michigan have delved deeper into the relationship between manganese deficiency and inflammatory bowel disease and found that low levels of the micronutrient can exacerbate intestinal injury ...
Sep 12, 2024
0
24
Innovative research has provided compelling evidence that perceived stress can directly trigger the relapse of psoriatic skin lesions. The study, presented at the European Academy of Dermatology and Venereology (EADV) Congress ...
Sep 26, 2024
0
1
The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis.
Sep 19, 2024
0
1
Northwestern Medicine scientists have discovered a new mechanism that controls a specialized group of T-cells, known as regulatory T-cells, and may serve as potential therapeutic targets to treat inflammatory disorders and ...
Oct 3, 2024
0
22
For patients with moderate-to-severe atopic dermatitis (AD), lebrikizumab has long-term efficacy, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. ...
Oct 5, 2024
0
0
One in four participants in a European wide study aimed at detecting early signs of psoriasis showed signs of possible arthritis.
Sep 13, 2024
0
1
In 2019, Steven Mansoor, M.D., Ph.D., a physician–scientist at Oregon Health & Science University, and his research team made a groundbreaking discovery: They determined the first complete structure of a protein linked ...
Oct 7, 2024
0
29
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.
Sep 17, 2024
0
0
